Logo image of VTAK

CATHETER PRECISION INC (VTAK) Stock Fundamental Analysis

USA - NYSEARCA:VTAK - US74933X7084 - Common Stock

2.56 USD
-0.04 (-1.54%)
Last: 10/3/2025, 8:11:21 PM
2.5405 USD
-0.02 (-0.76%)
After Hours: 10/3/2025, 8:11:21 PM
Fundamental Rating

2

Overall VTAK gets a fundamental rating of 2 out of 10. We evaluated VTAK against 191 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of VTAK have multiple concerns. VTAK shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VTAK has reported negative net income.
In the past year VTAK has reported a negative cash flow from operations.
In the past 5 years VTAK always reported negative net income.
VTAK had a negative operating cash flow in each of the past 5 years.
VTAK Yearly Net Income VS EBIT VS OCF VS FCFVTAK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

VTAK has a worse Return On Assets (-93.43%) than 78.53% of its industry peers.
VTAK's Return On Equity of -292.71% is on the low side compared to the rest of the industry. VTAK is outperformed by 77.49% of its industry peers.
Industry RankSector Rank
ROA -93.43%
ROE -292.71%
ROIC N/A
ROA(3y)-156.76%
ROA(5y)-139.44%
ROE(3y)-270.77%
ROE(5y)-233.22%
ROIC(3y)N/A
ROIC(5y)N/A
VTAK Yearly ROA, ROE, ROICVTAK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

Looking at the Gross Margin, with a value of 90.02%, VTAK belongs to the top of the industry, outperforming 97.91% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for VTAK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VTAK Yearly Profit, Operating, Gross MarginsVTAK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -50K -100K -150K

More info and screens

1

2. Health

2.1 Basic Checks

VTAK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VTAK has been increased compared to 1 year ago.
The debt/assets ratio for VTAK is higher compared to a year ago.
VTAK Yearly Shares OutstandingVTAK Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100K 200K 300K 400K
VTAK Yearly Total Debt VS Total AssetsVTAK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

VTAK has an Altman-Z score of -18.36. This is a bad value and indicates that VTAK is not financially healthy and even has some risk of bankruptcy.
VTAK has a Altman-Z score of -18.36. This is amonst the worse of the industry: VTAK underperforms 88.48% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that VTAK is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.01, VTAK is in the better half of the industry, outperforming 69.63% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -18.36
ROIC/WACCN/A
WACC7.57%
VTAK Yearly LT Debt VS Equity VS FCFVTAK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M -30M

2.3 Liquidity

VTAK has a Current Ratio of 0.21. This is a bad value and indicates that VTAK is not financially healthy enough and could expect problems in meeting its short term obligations.
VTAK has a Current ratio of 0.21. This is amonst the worse of the industry: VTAK underperforms 95.81% of its industry peers.
A Quick Ratio of 0.19 indicates that VTAK may have some problems paying its short term obligations.
With a Quick ratio value of 0.19, VTAK is not doing good in the industry: 95.81% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.21
Quick Ratio 0.19
VTAK Yearly Current Assets VS Current LiabilitesVTAK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.07% over the past year.
The Revenue has grown by 9.57% in the past year. This is quite good.
VTAK shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 167.26% yearly.
EPS 1Y (TTM)12.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-84.72%
Revenue 1Y (TTM)9.57%
Revenue growth 3Y167.27%
Revenue growth 5YN/A
Sales Q2Q%74.39%

3.2 Future

The Earnings Per Share is expected to grow by 40.75% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 312.31% on average over the next years. This is a very strong growth
EPS Next Y96.27%
EPS Next 2Y40.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year533.33%
Revenue Next 2Y312.31%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VTAK Yearly Revenue VS EstimatesVTAK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
VTAK Yearly EPS VS EstimatesVTAK Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2023 2024 2025 2026 -20K -40K -60K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

VTAK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VTAK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VTAK Price Earnings VS Forward Price EarningsVTAK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VTAK Per share dataVTAK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150

4.3 Compensation for Growth

A more expensive valuation may be justified as VTAK's earnings are expected to grow with 40.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.75%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VTAK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CATHETER PRECISION INC

NYSEARCA:VTAK (10/3/2025, 8:11:21 PM)

After market: 2.5405 -0.02 (-0.76%)

2.56

-0.04 (-1.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-11 2025-11-11/amc
Inst Owners1.76%
Inst Owner Change-45.05%
Ins Owners0.83%
Ins Owner Change0%
Market Cap3.81M
Analysts85.71
Price Target38.76 (1414.06%)
Short Float %N/A
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-52.29%
Min Revenue beat(2)-53.27%
Max Revenue beat(2)-51.31%
Revenue beat(4)0
Avg Revenue beat(4)-66.02%
Min Revenue beat(4)-91.15%
Max Revenue beat(4)-51.31%
Revenue beat(8)0
Avg Revenue beat(8)-67.73%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1800%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.55
P/FCF N/A
P/OCF N/A
P/B 0.4
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-172.42
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-7.9
FCFYN/A
OCF(TTM)-7.86
OCFYN/A
SpS0.39
BVpS6.44
TBVpS-12.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -93.43%
ROE -292.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.02%
FCFM N/A
ROA(3y)-156.76%
ROA(5y)-139.44%
ROE(3y)-270.77%
ROE(5y)-233.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.6%
Cap/Sales 11.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.21
Quick Ratio 0.19
Altman-Z -18.36
F-Score3
WACC7.57%
ROIC/WACCN/A
Cap/Depr(3y)3.63%
Cap/Depr(5y)N/A
Cap/Sales(3y)51.53%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-84.72%
EPS Next Y96.27%
EPS Next 2Y40.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)9.57%
Revenue growth 3Y167.27%
Revenue growth 5YN/A
Sales Q2Q%74.39%
Revenue Next Year533.33%
Revenue Next 2Y312.31%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y62.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y62.89%
OCF growth 3YN/A
OCF growth 5YN/A